Show simple item record

dc.contributor.authorAkhoundova Sanoyan, D
dc.contributor.authorMcNamara, Mairead G
dc.contributor.authorLamarca, Angela
dc.contributor.authorValle, Juan W
dc.date.accessioned2020-08-10T08:09:19Z
dc.date.available2020-08-10T08:09:19Z
dc.date.issued2020en
dc.identifier.citationAkhoundova Sanoyan D, McNamara MG, Lamarca A, Valle JW. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Curr Opin Oncol. 2020;32(4):364-9.en
dc.identifier.pmid32541326en
dc.identifier.doi10.1097/cco.0000000000000643en
dc.identifier.urihttp://hdl.handle.net/10541/623081
dc.description.abstractPurpose of review: Biliary tract cancers (BTCs) have a poor prognosis; most patients present with advanced disease and, even after surgical resection for early-stage disease local and distant relapses are frequent. Involved resection margins and lymph node involvement are the most relevant known adverse prognostic factors. Historically clinicians have made clinical decisions based on data from institutional series and uncontrolled studies, with their inherent limitations. In this review, data from recently-reported prospective randomized trials are reviewed and clinical implications discussed. Recent findings: Results from prospective randomized phase III trials (namely BILCAP, PRODIGE-12, and BCAT) are reviewed: none of the studies met their primary endpoint by intention-to-treat analysis. However, following a per-protocol sensitivity analysis of the BILCAP study, adjuvant capecitabine (for 6 months) showed a clinically-relevant improvement in overall survival and provides reference data for future clinical trials. Summary: Adjuvant chemotherapy with capecitabine should be considered following curative resection of BTC. Identification of benefit in anatomical subgroups is ongoing and future trials should also consider the implication of molecular subtypes of BTC (for prognostic impact and on-target therapeutic options).en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/cco.0000000000000643en
dc.titleAdjuvant chemotherapy in biliary tract cancer: state of the art and future perspectivesen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.en
dc.identifier.journalCurrent Opinion in Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record